AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
ABBV News
AbbVie (NYSE:ABBV) snapped six consecutive sessions of losses on Thursday as the stock ended 0.29% lower at $226.87. Since October 8, the stock has closed in t...
Abbvie ((ABBV)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...
Abbvie ((ABBV)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...
Analyst ratings
61%
of 31 ratingsMore ABBV News
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model ba...
Investors should be able to count on these stocks to deliver steady and growing income over the long term. The idea of steady money flowing in, year after year...
If you are staring at AbbVie's share price and wondering whether now is the right time to buy or hold, you are definitely not alone. AbbVie has been making plen...
On CNBC's “Halftime Report Final Trades,” on Monday, Jim Lebenthal, partner at Cerity Partners, said AbbVie Inc (NYSE:ABBV) has gained 30% this year. The stock...
Erste Group downgraded AbbVie (ABBV) to Hold from Buy. The company recently announced a significant guidance reduction due to a required write-off of research a...
(RTTNews) - AbbVie (ABBV) Monday announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the i...
AbbVie (ABBV) announced it will unveil new data from its robust antibody-drug conjugate platform at the 2025 European Society for Medical Oncology Congress, tak...